Header Logo

Connection

Sudhir Agrawal to Female

This is a "connection" page, showing publications Sudhir Agrawal has written about Female.
Connection Strength

0.406
  1. Zhu FG, Jiang W, Bhagat L, Wang D, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S. A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity. 2013 Nov; 46(7):419-28.
    View in: PubMed
    Score: 0.024
  2. Kandimalla ER, Bhagat L, Wang D, Yu D, Sullivan T, La Monica N, Agrawal S. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 2013 Apr 01; 41(6):3947-61.
    View in: PubMed
    Score: 0.024
  3. Jiang W, Zhu FG, Bhagat L, Yu D, Tang JX, Kandimalla ER, La Monica N, Agrawal S. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013 Jul; 133(7):1777-84.
    View in: PubMed
    Score: 0.023
  4. Lan T, Wang D, Bhagat L, Philbin VJ, Yu D, Tang JX, Putta MR, Sullivan T, La Monica N, Kandimalla ER, Agrawal S. Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. Org Biomol Chem. 2013 Feb 14; 11(6):1049-58.
    View in: PubMed
    Score: 0.023
  5. Lan T, Dai M, Wang D, Zhu FG, Kandimalla ER, Agrawal S. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies. J Med Chem. 2009 Nov 12; 52(21):6871-9.
    View in: PubMed
    Score: 0.019
  6. Yu D, Wang D, Zhu FG, Bhagat L, Dai M, Kandimalla ER, Agrawal S. Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem. 2009 Aug 27; 52(16):5108-14.
    View in: PubMed
    Score: 0.019
  7. Wang D, Bhagat L, Yu D, Zhu FG, Tang JX, Kandimalla ER, Agrawal S. Oligodeoxyribonucleotide-based antagonists for Toll-like receptors 7 and 9. J Med Chem. 2009 Jan 22; 52(2):551-8.
    View in: PubMed
    Score: 0.018
  8. Yu D, Putta MR, Bhagat L, Dai M, Wang D, Trombino AF, Sullivan T, Kandimalla ER, Agrawal S. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother. 2008 Dec; 52(12):4320-5.
    View in: PubMed
    Score: 0.017
  9. Zhu FG, Kandimalla ER, Yu D, Agrawal S. Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. J Allergy Clin Immunol. 2007 Sep; 120(3):631-7.
    View in: PubMed
    Score: 0.016
  10. Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res. 2006; 34(11):3231-8.
    View in: PubMed
    Score: 0.015
  11. Li Y, Kandimalla ER, Yu D, Agrawal S. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. Int Immunopharmacol. 2005 Jun; 5(6):981-91.
    View in: PubMed
    Score: 0.014
  12. Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc Natl Acad Sci U S A. 2005 May 10; 102(19):6925-30.
    View in: PubMed
    Score: 0.014
  13. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine. 2005 Apr 08; 23(20):2614-22.
    View in: PubMed
    Score: 0.014
  14. Zhu FG, Kandimalla ER, Yu D, Tang JX, Agrawal S. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol. 2004 Jul; 4(7):851-62.
    View in: PubMed
    Score: 0.013
  15. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol. 2004 Apr; 24(4):901-8.
    View in: PubMed
    Score: 0.013
  16. Agrawal DK, Edwan J, Kandimalla ER, Yu D, Bhagat L, Wang D, Agrawal S. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan; 4(1):127-38.
    View in: PubMed
    Score: 0.013
  17. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14303-8.
    View in: PubMed
    Score: 0.012
  18. Kandimalla ER, Bhagat L, Cong YP, Pandey RK, Yu D, Zhao Q, Agrawal S. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun. 2003 Jul 11; 306(4):948-53.
    View in: PubMed
    Score: 0.012
  19. Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER, Zhang R, Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun. 2003 Jan 24; 300(4):853-61.
    View in: PubMed
    Score: 0.012
  20. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J, Agrawal S. 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002 Oct 15; 30(20):4460-9.
    View in: PubMed
    Score: 0.011
  21. Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S. Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem. 2002 Sep-Oct; 13(5):966-74.
    View in: PubMed
    Score: 0.011
  22. Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, Chen SF. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002 Jul; 21(1):65-72.
    View in: PubMed
    Score: 0.011
  23. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Res. 2002 Apr 01; 30(7):1613-9.
    View in: PubMed
    Score: 0.011
  24. Henriques-Pons A, Yu Q, Rayavarapu S, Cohen TV, Ampong B, Cha HJ, Jahnke V, Van der Meulen J, Wang D, Jiang W, Kandimalla ER, Agrawal S, Spurney CF, Nagaraju K. Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Hum Mol Genet. 2014 May 15; 23(10):2604-17.
    View in: PubMed
    Score: 0.006
  25. Kandimalla ER, Struthers M, Bett AJ, Wisniewski T, Dubey SA, Jiang W, Precopio M, Sun Z, Wang H, Lan T, Agrawal S, Casimiro DR. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cell Immunol. 2011; 270(2):126-34.
    View in: PubMed
    Score: 0.005
  26. Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine. 2010 Apr 30; 28(20):3522-30.
    View in: PubMed
    Score: 0.005
  27. Struthers M, Bett AJ, Wisniewski T, Dubey SA, Precopio M, Jiang W, Sun Z, Wang H, Nowak I, Putta MR, Yu D, Tang JX, Kandimalla ER, Agrawal S, Casimiro DR. Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cell Immunol. 2010; 263(1):105-13.
    View in: PubMed
    Score: 0.005
  28. Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 2009 Nov 15; 15(22):6921-30.
    View in: PubMed
    Score: 0.005
  29. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res. 2009 Mar 01; 15(5):1575-84.
    View in: PubMed
    Score: 0.004
  30. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther. 2006 Aug; 5(8):2106-14.
    View in: PubMed
    Score: 0.004
  31. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther. 2006 Jun; 5(6):1585-92.
    View in: PubMed
    Score: 0.004
  32. Trabattoni D, Clivio A, Bray DH, Bhagat L, Beltrami S, Maffeis G, Cesana E, Lowry P, Lissoni F, Kandimalla ER, Sullivan T, Agrawal S, Bartholomew R, Clerici M. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine. 2006 Feb 27; 24(9):1470-7.
    View in: PubMed
    Score: 0.004
  33. Bjersing JL, Tarkowski A, Kandimalla ER, Karlsson H, Agrawal S, Collins LV. Impact of site-specific nucleobase deletions on the arthritogenicity of DNA. Inflammation. 2004 Jun; 28(3):159-68.
    View in: PubMed
    Score: 0.003
  34. Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, Zhang R. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002 Jul; 21(1):73-80.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.